Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Liabilities (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Total Liabilities for 10 consecutive years, with $341.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 49.8% to $341.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $341.1 million, a 49.8% increase, with the full-year FY2025 number at $341.1 million, up 49.8% from a year prior.
  • Total Liabilities was $341.1 million for Q4 2025 at Rhythm Pharmaceuticals, up from $211.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $341.1 million in Q4 2025 to a low of $33.6 million in Q3 2021.
  • A 5-year average of $147.1 million and a median of $142.2 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: surged 223.06% in 2022, then increased 0.15% in 2025.
  • Rhythm Pharmaceuticals' Total Liabilities stood at $45.4 million in 2021, then soared by 160.55% to $118.2 million in 2022, then skyrocketed by 37.87% to $163.0 million in 2023, then skyrocketed by 39.72% to $227.7 million in 2024, then soared by 49.8% to $341.1 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Total Liabilities are $341.1 million (Q4 2025), $211.2 million (Q3 2025), and $239.2 million (Q2 2025).